Asia-Pacific DTC Laboratory Testing Market by Application (Genetic Testing {Ancestry, Disease Risk [Cancer, Cardiac, Neurological], Carrier Status}, Diabetes, COVID, Routine, Thyroid), and Sample Type (Blood, Saliva, Urine) - Forecast to 2030

The Asia-Pacific DTC Laboratory Testing Market is projected to reach $1.58 billion by 2030, at a CAGR of 12.8% from 2024 to 2030. Direct-to-consumer or DTC tests are the ones that are self-ordered by consumers without the involvement of their healthcare providers. The sample that is collected from the consumer is processed at a laboratory, and the results are then sent directly to the consumer.

The growth of the Asia-Pacific DTC Laboratory testing market is driven by several factors, including the rising incidence of chronic diseases and sexually transmitted diseases, high disposable income, increased consumer awareness, increasing awareness about personal health management, benefits of DTC laboratory testing such as high convenience, affordability, and accessibility, increasing prevalence of chronic and infectious diseases, the increasing cost of healthcare, and the rising elderly population. Factors such as the growing adoption of telehealth, expansion in emerging economies, and the increasing penetration of pharmacogenomic testing in DTC laboratory testing are a few of the opportunities that would help grow the market in the future. Genetic data privacy concerns, misinterpretation of test results, and lack of professional medical counseling could be considered challenges for the Asia-Pacific DTC Laboratory testing market. However, sample integrity and interference issues, regulatory concerns, lack of reimbursement, and the limited test portfolio compared to conventional laboratory testing restrain the growth of the market.

Click here to: Get Free Sample Pages of this Report

Ease of Accessibility to DTC Tests and Effective Marketing to Consumers Drive Market Growth

Over the last few years, consumers have been actively participating in decisions affecting their health, enabling people to be informed of their health and lead healthy lifestyles. Clinical laboratory testing is an important part of healthcare. These tests can be ordered online or bought from pharmacies without any prescription, making them easy to access for consumers. The easy accessibility and convenience of ordering the tests online also attract customers.

Companies operating in this market are conducting marketing campaigns and advertisements to interest consumers and inform them about the benefits of DTC tests. This encourages customers to order these tests without needing to consult a physician. Consumers can get personalized information about their health, disease risk, and other traits and gain awareness of their genetic predisposition to illnesses using these DTC tests. Thus, ease of accessibility to DTC tests and effective marketing to consumers.

Increasing Population Coupled with Rising Chronic Diseases

The rising prevalence of chronic & infectious diseases is expected to drive the demand for DTC laboratory testing. Many DTC laboratory testing companies are offering tests for diagnosing infectious diseases and monitoring chronic diseases. China has the world’s largest population, with about 1.45 billion people as of 2024. The sheer large population of the country leads to high demand for various healthcare services, including DTC Laboratory services. The geriatric population is also estimated to reach 225 million in 2030 from 170 million in 2020. The elderly population is more prone to chronic and infectious diseases due to immune dysfunction, malnutrition, and aging-related physiological changes. The rising disease burden can directly affect a country’s social and economic status. Thus, it is necessary to adopt early diagnostic procedures to minimize the burden of these diseases. The large population, the rise in the geriatric population, and the rising prevalence of diseases have led to increased demand for DTC Laboratory testing. Thus, the advantages of DTC lab testing, such as discretion & confidentiality and the increased prevalence of sexually transmitted diseases, are expected to drive the demand for DTC lab testing.

Key Findings of the Asia-Pacific DTC Laboratory Testing Market Study:

The Genetic Testing Segment is Expected to Account for the Largest Share of the Market in 2024

Among all the applications, in 2024, the genetic testing segment is expected to account for the largest share of the market. DTC genetic tests are those that are provided directly to consumers without involving a healthcare provider. This testing generally offers a wide range of genetic tests that can be helpful to provide consumers with information about their ancestry, health risks, and traits. This segment is driven by factors such as increasing awareness regarding personal health management, high curiosity about self-ancestry, strong marketing strategies by the companies, rising prevalence of various genetic & chronic diseases, and high demand for personalized testing services.

The Blood Segment is Expected to Account for the Largest Share of the Market in 2024

Among sample types, in 2024, the blood segment is expected to account for the largest share of the market. The blood sample is collected from consumers to test conditions such as diabetes, routine clinical testing, thyroid function, and sexually transmitted disease testing, among others, in order to gain insight into how the organs are functioning. Blood samples are collected using a lancet or a needle that is present in the kit provided to carry out the test. This segment is driven by factors such as a large variety of available tests using blood samples, increasing prevalence of various chronic diseases, and increasing consumer awareness regarding the monitoring of chronic diseases.

Key Players

The key players profiled in the Asia-Pacific DTC Laboratory testing market report are Metropolis Healthcare Limited (India), SRL Limited (India), Hirotsu Bio Science (Japan), Mapmygenome India Limited (India), Genesis Healthcare Co. (Japan), Augmentum Diagnostics (India), Apollo Health and Lifestyle Limited (India), WeGene (China), GeseDNATechnology LLP (China), Laboratory Corporation of America Holdings (U.S.), LetsGetChecked, Inc. (U.S.), and 23andMe Holding Co. (U.S.).

The report includes a competitive landscape based on an extensive assessment of the market based on application, sample type, and geography. The report also provides insights into the geographic presence of major market players and their key growth strategies in the last three to four years.

Scope of the Report:

Asia-Pacific DTC Laboratory Testing Market, by Application

• Genetic Testing
  • Ancestry/Genealogy
  • Disease Risk Assessment
    • Cancer
    • Cardiovascular Diseases
    • Neurological Diseases
    • Other Diseases
      (Note: Disease risk assessment testing for other diseases includes celiac disease, alpha-1 antitrypsin deficiency, factor XI deficiency, glucose-6-phosphate dehydrogenase deficiency, etc.)
  • Carrier Status
  • Other Genetic Tests
    (Note: Other genetic tests primarily include direct-to-consumer genetic testing for pharmacogenomics, skin care DNA tests, and nutrigenomic testing.)
• Diabetes Testing
• Routine Clinical Testing
• Thyroid Function Testing
• COVID-19 Testing
• Sexually Transmitted Disease Testing
• Other Applications
  (Note: Other applications primarily include drug screening, infectious disease testing [Tuberculosis, Chicken pox, Measles, Mumps, Rubella, UTI], allergy testing, fertility, pregnancy, and nutritional testing.)

Asia-Pacific DTC Laboratory Testing Market, by Sample Type

• Blood
• Saliva
• Urine
• Other Samples
  (Note: Other samples primarily include stool, nasopharyngeal swab, vaginal swab, buccal swab, and semen.)

Asia-Pacific DTC Laboratory Testing Market, by Country

• China
• Japan
• India
• Australia
• South Korea
• Indonesia
• Thailand
• Malaysia
• Singapore
• Philippines
• Vietnam
• Rest of Asia-Pacific (RoAPAC)

Key questions answered in the report: